Cullinan Therapeutics To Present Positive Phase 3 REZILIENT3 Results For Zipalertinib In EGFR Exon 20+ Lung Cancer; To Host A Virtual Event On Monday, September 14, 2026, At 8:00 a.m. ET

뉴스 본문을 불러오고 있어요.

Cullinan Therapeutics To Present Positive Phase 3 REZILIENT3 Results For Zipalertinib In EGFR Exon 20+ Lung Cancer; To Host A Virtual Event On Monday, September 14, 2026, At 8:00 a.m. ET | 웨이프 WAPE

Cullinan Therapeutics To Present Positive Phase 3 REZILIENT3 Results For Zipalertinib In EGFR Exon 20+ Lung Cancer; To Host A Virtual Event On Monday, September 14, 2026, At 8:00 a.m. ET

기사 요약

관련 종목

댓글 —